ArticleCureus2025
Usefulness of 11C-Methionine Positron Emission Tomography for Differentiating Tumor Recurrence and Necrosis in Ethmoid Sinus Cancer With Intracranial Extension.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
For head and neck cancer, treatment efficacy and recurrence are often assessed by morphological imaging methods such as CT and MRI. However, these techniques are sometimes ineffective for distinguishing qualitative changes in tumors following treatment. Here, we report the case of a 50-year-old male patient who received chemoradiotherapy for head and neck squamous cell carcinoma with intracranial extension. Following treatment, the patient's symptoms subsided, and MRI at two and six months demonstrated tumor shrinkage. Six months after treatment, fluorodeoxyglucose (FDG) positron emission tomography (PET) revealed changes in the intracranial lesions, which were difficult to distinguish between tumor recurrence and necrosis. Consequently, we used 11C-methionine (MET) PET during follow-up. The findings from MET PET showed no evidence of disease recurrence; thus, the lesions were subsequently monitored for necrotic changes. This case suggests the potential utility of MET PET for differentiating recurrence from necrosis in head and neck cancers with intracranial extension. Further studies with larger cohorts are warranted to clarify its diagnostic accuracy and establish appropriate evaluation criteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.